Showing 101-110 of 9380 results for "".
- Lutikizumab Meets Primary Endpoint in Phase 3 Hidradenitis Suppurativa Trialhttps://practicaldermatology.com/news/lutikizumab-meets-primary-endpoint-in-phase-3-hidradenitis-suppurativa-trial/2488774/AbbVie announced positive topline results from the Phase 3 INTREPID trial evaluating lutikizumab, an investigational dual IL-1α/IL-1β antagonist, in adults and adolescents with moderate-to-severe hidradenitis suppurativa (HS). The randomized, double-blind, placebo-co
- Melanoma Risk Prediction Models Show Moderate Accuracy in Large Australian Cohorthttps://practicaldermatology.com/news/melanoma-risk-prediction-models-show-moderate-accuracy-in-large-australian-cohort/2488770/Six published melanoma risk prediction models demonstrated varying accuracy in identifying individuals who developed melanoma, with most underestimating absolute risk, according to a cohort study published in JAMA Dermatology. Melanoma Risk Prediction Accuracy and Study Findings<
- Sun Pharma, Mount Sinai Leaders Discuss Long-Term Vision Behind $2.5 Million Dermatology Endowmenthttps://practicaldermatology.com/news/sun-pharma-mount-sinai-leaders-discuss-long-term-vision-behind-25-million-dermatology-endowment/2488752/Sun Pharma’s’ $2.5 million endowed professorship at the Icahn School of Medicine at Mount Sinai represents an extension of a longstanding collaboration centered
- Phase 3 Trial of Oral Minoxidil Formulation Meets Primary Endpoints in Male Pattern Hair Losshttps://practicaldermatology.com/news/phase-3-trial-of-oral-minoxidil-formulation-meets-primary-endpoints-in-male-pattern-hair-loss/2488751/Veradermics announced positive topline results from its Phase 3 Study 304 evaluating VDPHL01, an investigational extended-release oral minoxidil formulation, in men with mild-to-moderate androgenetic alopecia. The randomized, double-blind, placebo-controlled trial met both co-primary endpoints at
- "20 Tips in 20 Minutes" Offers Practical Pearls at Fall Clinicalhttps://practicaldermatology.com/news/20-tips-in-20-minutes-offers-practical-pearls-at-fall-clinical/2488740/Five dermatologists shared rapid-fire clinical, procedural, and practice-management advice, ranging from alopecia photography and nail examination to infantile hemangiomas, reimbursement, and patient communication at the 2026 Fall Clinical Dermatology Conference. The fast-moving "20 Tips i
- Expert Panel Proposes Practical Treatment Algorithm for Pediatric Molluscum Contagiosumhttps://practicaldermatology.com/news/expert-panel-proposes-practical-treatment-algorithm-for-pediatric-molluscum-contagiosum/2488716/A pediatric dermatology expert panel has proposed a practical treatment algorithm for molluscum contagiosum that emphasizes disease severity, family preferences, and shared decision-making. Presented in a 2026 Fall Clinical Dermatology Conference poster, the framework addresses a common, transmis
- Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/dupilumab-associated-with-lower-atopic-march-risk-in-pediatric-atopic-dermatitis/2488713/Children with atopic dermatitis (AD) who initiated dupilumab had a lower observed risk of developing additional atopic conditions than matched patients treated with systemic corticosteroids, according to a retrospective US claims study presented at the 2026 Fall Clinical Dermatology Conference.</
- GLP-1 Medication Use Shows No Apparent Impact on Icotrokinra Outcomes in Phase 3 Psoriasis Analysishttps://practicaldermatology.com/news/glp-1-medication-use-shows-no-apparent-impact-on-icotrokinra-outcomes-in-phase-3-psoriasis-analysis/2488675/Concomitant use of glucagon-like peptide-1 (GLP-1)–based medications was not associated with an apparent difference in icotrokinra efficacy, safety, or pharmacokinetics among patients with plaque psoriasis, according to pooled post hoc analyses of the phase 3 ICONIC clinical trial program present
- Comparison Examines GEP Performance Against Melanoma SLNB Risk Thresholdshttps://practicaldermatology.com/news/comparison-examines-gep-performance-against-melanoma-slnb-risk-thresholds/2488674/A comparison of two prospective studies evaluating gene expression profiling (GEP) tests combined with clinicopathologic factors found differences in their ability to identify patients with cutaneous melanoma at low risk for sentinel lymph node (SLN) positivity.1
- New Imaging Approach Shows High Agreement in Mohs Margin Assessment: Studyhttps://practicaldermatology.com/news/2-new-imaging-approach-shows-high-agreement-in-mohs-margin-assessment/2488673/A recent Modern Pathology study reported found that ex vivo fluorescence confocal microscopy (EVFCM) achieved high overall diagnostic accuracy in assessing surgical margins during Mohs surgery for nonmelanoma skin cancer (NMSC). EVFCM Shows Strong Agreement With Histopathology i